 Home > Biochemistry News > Biotechnology News > Gritstone bio's innovative cancer vaccine enters phase 2/3 clinical trial

Gritstone bio's innovative cancer vaccine enters phase 2/3 clinical trial

 Last Update: 2022-02-23
 Source: Internet
 Author: User

Tags

maintenance mechanic

thp 1 cells

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On January 13, 2022, Gritstone bio announced that it is evaluating a personalized cancer vaccine in combination with an immune checkpoint inhibitor as first-line maintenance therapy for 2/2 of patients with newly diagnosed microsatellite stable metastatic colorectal cancer (MSS-CRC).

The cancer vaccine is designed by taking biopsies from patients, sequencing the tumors, and then using a proprietary artificial intelligence platform to screen for tumor-specific neoantigens

Self-amplifying mRNA vectors contain mRNA encoding the selected target antigen and RNA polymerase

Image source: Gritstone bio's official website

The Phase 2/3 trial was designed to evaluate this neoantigen cancer vaccine in combination with the PD-L1 inhibitor atezolizumab (atezolizumab) and the CTLA-4 inhibitor Yervoy (ipilimumab) as first-line maintenance therapy in patients already receiving fluorouracil Efficacy of induction therapy with oxaliplatin, oxaliplatin, and bevacizumab in patients with newly diagnosed metastatic MSS-CRC

In addition, the company reported updated overall survival (OS) data from a Phase 1/2 trial of the cancer vaccine, in combination with Opdivo and Yervoy, in patients with advanced solid tumors

References:

[1] Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC).

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.